Evidence map›Paper›PMID 33374332›Full record

ArticleGenes2020

Kathryn Hughes Barry, Kareshma Mohanty, Patricia A Erickson, Difei Wang, Jianxin Shi, Gary Rose, Ashley Cellini, Kimberly Clark, Nicholas Ambulos, Jing Yin and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Epigenetics in prostate cancer treatment.Journal of translational genetics and genomics · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Kathryn Hughes BarryDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Kareshma MohantyDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Patricia A EricksonDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Difei WangBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
Jianxin ShiBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
Gary RoseDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Ashley CelliniPathology Biorepository Shared Service, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Kimberly ClarkPathology Biorepository Shared Service, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Nicholas AmbulosProgram in Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Jing YinProgram in Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Liying YanEpigenDx, Inc., Hopkinton, MA 01748, USA.
Matthew PoulinEpigenDx, Inc., Hopkinton, MA 01748, USA.
Ann MeyerEpigenDx, Inc., Hopkinton, MA 01748, USA.
Yuji ZhangDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Søren M BentzenDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Allen BurkeDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Arif HussainProgram in Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Sonja I BerndtOccupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
University of Maryland, Baltimore · USDivision of Cancer Epidemiology and GeneticsU-M Rogel Cancer Center

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Vu H. Duong · 2008 to 2026
$51.0M
Epigenomic and transcriptomic markers of aggressive prostate cancer among African American menK07CA230182 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI BARRY, KATHRYN HUGHES · 2018 to 2023
$827k
Optimization of Multi-Modal Therapies in Pre-clinical models of Prostate CancerI01BX000545 · VA · BALTIMORE VA MEDICAL CENTER · PI HUSSAIN, ARIF · 2009 to 2021
–
BLRD VA I01 BX000545NCI NIH HHS K07 CA230182NCI NIH HHS P30CA134274
6 · The paper itself

Abstract

Increasing evidence suggests a role of epigenetic mechanisms at chromosome 8q24, an important cancer genetic susceptibility region, in prostate cancer. We investigated whether

Indexed as

AdultAgedBiomarkers, TumorCohort StudiesCpG IslandsDNA MethylationEpigenesis, GeneticExonsGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm GradingProstateProstatectomyProstatic NeoplasmsBiomarkers, TumorMYC protein, humanPRNCR1 long non-coding RNA, humanProto-Oncogene Proteins c-mycRNA, Long Noncodingaggressive diseaseDNA methylationGleason score (GS)MYCnon-coding RNAs (ncRNAs)prostate cancerRNA expressiontumor tissue biomarkers

Identifiers

PMID33374332
PMCPMC7823928
OpenAlexW3115435558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.